Relapsed/refractory classical Hodgkin lymphoma treated with pulsed Boom-Boom radiotherapy combined with a PD-1 inhibitor and decitabine: Two case reports

Author:

Wang Chen1,Xue Zhuang2,Zou Benkui2,Shi Pengyue2,Yue Jinbo1

Affiliation:

1. Shandong University

2. Affiliated Cancer Hospital of Shandong First Medical University

Abstract

Abstract

Hodgkin lymphoma (HL), characterized by cancerous Reed-Sternberg cells within an inflammatory milieu, poses challenges in relapsed or refractory cases. Current standard treatments, including salvage chemotherapy and autologous stem cell transplantation (ASCT), have limitations in achieving long-term remission. Herein, we present two cases of nodular sclerosing relapsed/refractory Hodgkin's lymphoma treated with personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR) in combination with a PD-1 inhibitor and Decitabine. Patients underwent PULSAR (2Gy/dose x 2f D1-2 q3w) for recurrent lesions along with PD-1 monoclonal antibody (200mg D0 q3w) and Decitabine (10mg D1-5 q3w) for six cycles. Both patients achieved complete remission (CR) post-treatment, enabling subsequent ASCT and PD-1 maintenance therapy. Follow-up revealed prolonged survival without recurrence. PULSAR, by delivering radiation pulses at longer intervals, allows for tumor adaptation and immune response, potentially enhancing treatment efficacy and minimizing toxicity. Combined with immunotherapy and Decitabine, PULSAR shows promise in managing relapsed/refractory HL, warranting further investigation through clinical trials. This approach signifies a paradigm shift towards precision tumor therapy and immunomodulation in HL management.

Publisher

Springer Science and Business Media LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3